InnoCare Pharma’s A- and H-shares rose in tandem; A-shares climbed nearly 2%
while H-shares turned positive after the company’s wholly owned subsidiary
signed a licensing agreement with Eli Lilly that includes up to $3.25 bln in
milestone payments.
2026-09-24
InnoCare Pharma’s A- and H-shares rose in tandem; A-shares climbed nearly 2%
while H-shares turned positive after the company’s wholly owned subsidiary
signed a licensing agreement with Eli Lilly that includes up to $3.25 bln in
milestone payments.